Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 12:27:06 30/04/2024 am IST			5-day change	1st Jan Change
891.2 ^USD	+0.91%		-1.07%	+1.39%

26/04	Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	MT
26/04	Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	26/04	MT
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating	24/04	MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating	17/04	MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	17/04
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	15/04	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating	09/04	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	25/03	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	22/03	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	22/03	DJ
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating	13/03	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating	27/02	MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating	22/02	MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating	06/02	MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating	06/02	MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating	06/02	MT
Truist Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,045, Maintains Buy Rating	05/02	MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,076 Amid 'Underappreciated' Growth Prospects for Dupixent; Outperform Kept	05/02	MT
Barclays Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $1,020, Keeps Overweight Rating	05/02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,016 From $956, Keeps Overweight Rating	05/02	MT
Wells Fargo Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $980, Keeps Overweight Rating	05/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Analyst Reco.

Filters